抗TNF、乌司奴单抗与维得利珠单抗治疗克罗恩病24个月真实世界疗效比较:德国UMBRELLA-IBD登记处汇总分析
基于德国UMBRELLA-IBD数据仓库中1567例成人克罗恩病患者的前瞻性登记数据,采用倾向性评分逆概率加权比较抗TNF、乌司奴单抗与维得利珠单抗的疗效。诱导后临床缓解率抗TNF略高,24个月时乌司奴单抗略高于抗TNF;治疗持续性差异显著,阿达木单抗最高、英夫利西单抗最低。
要点
- 诱导后临床缓解率抗TNF略高于维得利珠单抗,24个月时乌司奴单抗略高于抗TNF。
- 24个月治疗持续性阿达木单抗最高81.4%,英夫利西单抗最低66.6%。
- HBI与EQ-VAS组间无显著差异,总体疗效较高但生物制剂间差异较小。
核心结论
- 克罗恩病总体疗效较高,生物制剂间仅存在小幅差异。
- 诱导结束时抗TNF临床缓解率略高于维得利珠单抗,24个月时乌司奴单抗略高于抗TNF。
- 治疗持续性在生物制剂间差异显著,持续性不能仅由临床缓解解释。
研究设计与样本
- 德国前瞻性克罗恩病登记处(BioCrohn、RUN-CD、VEDO-IBD)在UMBRELLA-IBD数据仓库中的个体患者数据汇总分析。
- 纳入1567例启动抗TNF(阿达木单抗或英夫利西单抗)、乌司奴单抗或维得利珠单抗的成人克罗恩病患者。
- 主要结局为24个月临床缓解(HBI≤4),采用倾向性评分逆概率加权进行组间比较。
主要发现
- 加权后诱导后临床缓解率:抗TNF 74.5%,乌司奴单抗69.4%,维得利珠单抗65.3%(p=0.035)。
- 加权后临床应答率:抗TNF 77.9%,乌司奴单抗73.5%,维得利珠单抗67.8%(p=0.015)。
- 24个月临床缓解率:抗TNF 53.4%,乌司奴单抗63.5%,维得利珠单抗58.7%;乌司奴单抗高于抗TNF(p=0.004)。
- 24个月治疗持续性差异显著(log-rank p<0.001):阿达木单抗81.4%,英夫利西单抗66.6%,乌司奴单抗78.6%,维得利珠单抗76.9%。
- HBI下降并保持低水平,EQ-VAS改善,组间无相关差异。
关键数值与推荐
- 临床缓解定义为HBI≤4。
- 诱导后临床缓解率抗TNF 74.5% vs 乌司奴单抗69.4% vs 维得利珠单抗65.3%(p=0.035)。
- 24个月临床缓解率乌司奴单抗63.5% vs 抗TNF 53.4%(p=0.004)。
- 治疗持续性log-rank p<0.001,阿达木单抗81.4%最高,英夫利西单抗66.6%最低。
临床怎么用
- 真实世界中三种生物制剂治疗克罗恩病24个月疗效均较高,选择时可综合考虑诱导与维持缓解的细微差异。
- 治疗持续性差异提示需关注不同生物制剂的长期耐受性与依从性,而非仅以临床缓解作为决策依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world evidence is needed to understand the comparative effectiveness of biologics in Crohn's disease (CD) under routine-care conditions. We conducted a pooled analysis of individual patient data from prospective German CD registries (BioCrohn, RUN-CD, VEDO-IBD) in the UMBRELLA-IBD data warehouse. METHODS: We included 1567 adults with CD who initiated anti-TNF therapy (adalimumab or infliximab), ustekinumab or vedolizumab. The main outcome was clinical remission (CR) at 24 months (HBI ≤ 4). Additional outcomes included HBI, EQ-VAS and treatment persistence over time. Between-group comparisons used propensity-score-based inverse probability of treatment weighting. RESULTS: After weighting, CR following induction was observed in a slightly higher proportion of patients initiating anti-TNF therapy (74.5%) than ustekinumab (69.4%) or vedolizumab (65.3%) (p = 0.035). Clinical response was 77.9%, 73.5% and 67.8%, respectively (p = 0.015). At 24 months, CR rates were similar in magnitude (anti-TNF, 53.4%; ustekinumab, 63.5%; vedolizumab, 58.7%) but were higher with ustekinumab than anti-TNF (p = 0.004). Over 24 months, treatment persistence differed (log-rank p < 0.001) and was highest for adalimumab (81.4%), lowest for infliximab (66.6%), and intermediate for ustekinumab (78.6%) and vedolizumab (76.9%). HBI decreased and remained low, and EQ-VAS improved, with no relevant between-group differences. CONCLUSION: Overall effectiveness in CD was high, with only small differences between biologic therapies. At the end of induction, CR was slightly higher with anti-TNF therapy than with vedolizumab, whereas at 24 months it was slightly higher with ustekinumab than with anti-TNF. Marked differences in treatment persistence among the evaluated biologics suggest that persistence as an endpoint is not fully explained by CR alone.
引用
- Bokemeyer A, Tran F, Plachta-Danielzik S, et al. Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany. Aliment Pharmacol Ther. 2026. PMID: 42298310. doi:10.1111/apt.70796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。